Derek Jantz

USPTO Granted Patents = 56 (Patent Applications = 89)

CIPO Patents = 1 (Patent Applications = 23)

EPO Patents = 33 (Patent Applications = 64)

Average Co-Inventor Count = 3.5

ph-index = 12

Forward Citations = 665(Granted Patents)

Forward Citations (Not Self Cited) = 497(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

38 out of 48

Precision Biosciences, Inc.

Pioneer Hi-bred International, Inc.

patents

4. 5 out of 16,338

E.i. Dupont De Nemours and Company

patents

5. 1 out of 104

Corteva Agriscience LLC

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Genetically-Modified T Cells

Engineered Meganucleases

Transgenic Trait Locus

Polynucleotides

Co-Stimulatory Domains

Hemophilia A Treatment

Hepatitis B Virus Genome

Retinitis Pigmentosa Treatment

Nucleic Acid Molecules

Viral Vectors

Mammalian Cell Lines

Male Sterile Plants

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448613 - Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene (2025-10-21),

2. 12351839 - Rationally-designed single-chain meganucleases with non-palindromic recognition sequences (2025-07-08),

3. 12338444 - Methods for producing a complex transgenic trait locus (2025-06-24),

4. 12006522 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-06-11),

5. 11993793 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-05-28),

6. 11753630 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2023-09-12),

7. 11680254 - Engineered meganucleases specific for recognition sequences in the PCSK9 gene (2023-06-20),

8. 11459576 - Methods for producing a complex transgenic trait locus (2022-10-04),

9. 11286291 - Co-stimulatory domains for use in genetically-modified cells (2022-03-29),

10. 11278632 - Engineered nucleases useful for treatment of hemophilia A (2022-03-22),

11. 11274285 - Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome (2022-03-15),

12. 11268065 - Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene (2022-03-08),

13. 11266693 - Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene (2022-03-08),

14. 11053484 - Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene (2021-07-06),

15. 10851358 - Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome (2020-12-01),

Title: The Innovative Journey of Derek Jantz

Introduction: Derek Jantz, a talented inventor based in Durham, NC, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Derek Jantz holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: Throughout his career, Derek Jantz has worked with leading tech companies to develop cutting-edge solutions that have revolutionized various industries. His passion for innovation and problem-solving has led to the successful implementation of numerous projects.

Collaborations: Derek Jantz has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Derek Jantz's relentless pursuit of innovation and his commitment to pushing the boundaries of technology make him a true pioneer in the world of inventions. His work continues to inspire and shape the future of technological advancements.

This text is generated by artificial intelligence and may not be accurate.